This is a preview of subscription content, log in via an institution to check access.
Reference
Miller K, et al. Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM study. 2013 Genitourinary Cancers Symposium : abstr. 17, 14 Feb 2012.
Rights and permissions
About this article
Cite this article
Enzalutamide a good quality choice for mCRPC. PharmacoEcon Outcomes News 673, 10 (2013). https://doi.org/10.1007/s40274-013-0219-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0219-7